Search Results
You are looking at 1 - 2 of 2 items for
- Author: Xiaojing Wei x
- Refine by access: All content x
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Xiaojing Wei in
Google Scholar
PubMed
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Yutian Tan in
Google Scholar
PubMed
Search for other papers by Jiaqi Huang in
Google Scholar
PubMed
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Ximing Dong in
Google Scholar
PubMed
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Weijie Feng in
Google Scholar
PubMed
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Tanglin Liu in
Google Scholar
PubMed
Search for other papers by Zhao Yang in
Google Scholar
PubMed
Search for other papers by Guiying Yang in
Google Scholar
PubMed
Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education of China, Xi’an Jiaotong University, Xi’an, China
Institute of Neuroscience, Translational Medicine Institute, Xi’an Jiaotong University Health Science Center, Xi’an, China
Search for other papers by Xiao Luo in
Google Scholar
PubMed
N1-methylnicotinamide (MNAM), a product of methylation of nicotinamide through nicotinamide N-methyltransferase, displays antidiabetic effects in male rodents. This study aimed to evaluate the ameliorative potential of MNAM on glucose metabolism in a gestational diabetes mellitus (GDM) model. C57BL/6N mice were fed with a high-fat diet (HFD) for 6 weeks before pregnancy and throughout gestation to establish the GDM model. Pregnant mice were treated with 0.3% or 1% MNAM during gestation. MNAM supplementation in CHOW diet and HFD both impaired glucose tolerance at gestational day 14.5 without changes in insulin tolerance. However, MNAM supplementation reduced hepatic lipid accumulation as well as mass and inflammation in visceral adipose tissue. MNAM treatment decreased GLUT4 mRNA and protein expression in skeletal muscle, where NAD+ salvage synthesis and antioxidant defenses were dampened. The NAD+/sirtuin system was enhanced in liver, which subsequently boosted hepatic gluconeogenesis. GLUT1 protein was diminished in placenta by MNAM. In addition, weight of placenta, fetus weight, and litter size were not affected by MNAM treatment. The decreased GLUT4 in skeletal muscle, boosted hepatic gluconeogenesis and dampened GLUT1 in placenta jointly contribute to the impairment of glucose tolerance tests by MNAM. Our data provide evidence for the careful usage of MNAM in treatment of GDM.
Search for other papers by Xiaopan Yang in
Google Scholar
PubMed
Search for other papers by Xiaojing Fan in
Google Scholar
PubMed
Search for other papers by Jiangyue Feng in
Google Scholar
PubMed
Search for other papers by Tinghui Fan in
Google Scholar
PubMed
Institute of Physical Science and Information Technology, Anhui University, Hefei, China
Search for other papers by Jingfei Li in
Google Scholar
PubMed
Search for other papers by Linfei Huang in
Google Scholar
PubMed
Search for other papers by Luming Wan in
Google Scholar
PubMed
Search for other papers by Huan Yang in
Google Scholar
PubMed
Search for other papers by Huilong Li in
Google Scholar
PubMed
Search for other papers by Jing Gong in
Google Scholar
PubMed
Search for other papers by Yanhong Zhang in
Google Scholar
PubMed
Search for other papers by Qi Gao in
Google Scholar
PubMed
Search for other papers by Fei Zheng in
Google Scholar
PubMed
Search for other papers by Lei Xu in
Google Scholar
PubMed
Search for other papers by Haotian Lin in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Dandan Zhang in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Hongbin Song in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Yufei Wang in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Xueping Ma in
Google Scholar
PubMed
Search for other papers by Zhiwei Sun in
Google Scholar
PubMed
Search for other papers by Cheng Cao in
Google Scholar
PubMed
Department of Laboratory, General Hospital of Armed Police Forces, Anhui Medical University, Hefei, China
Search for other papers by Xiaoli Yang in
Google Scholar
PubMed
Search for other papers by Hui Zhong in
Google Scholar
PubMed
Department of Endocrinology, Fifth Medical Center of Chinese PLA General Hospital, Beijing, China
Search for other papers by Yi Fang in
Google Scholar
PubMed
Search for other papers by Congwen Wei in
Google Scholar
PubMed
Golgi protein 73 (GP73), also called Golgi membrane protein 1 (GOLM1), is a resident Golgi type II transmembrane protein and is considered as a serum marker for the detection of a variety of cancers. A recent work revealed the role of the secreted GP73 in stimulating liver glucose production and systemic glucose homeostasis. Since exaggerated hepatic glucose production plays a key role in the pathogenesis of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), GP73 may thus represent a potential therapeutic target for treating diabetic patients with pathologically elevated levels. Here, in this study, we found that the circulating GP73 levels were significantly elevated in T2DM and positively correlated with hemoglobin A1c. Notably, the aberrantly upregulated GP73 levels were indispensable for the enhanced protein kinase A signaling pathway associated with diabetes. In diet-induced obese mouse model, GP73 siRNA primarily targeting liver tissue was potently effective in alleviating abnormal glucose metabolism. Ablation of GP73 from whole animals also exerted a profound glucose-lowering effect. Importantly, neutralizing circulating GP73 improved glucose metabolism in streptozotocin (STZ) and high-fat diet/STZ-induced diabetic mice. We thus concluded that GP73 was a feasible therapeutic target for the treatment of diabetes.